B-cell prolymphocytic leukemia expressing CD13 antigen. 1994

A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
Department of Immuno-Hematology, Kobe City General Hospital, Japan.

Although the expression of myeloid-associated antigen CD13 has been reported in aggressive B-cell chronic lymphocytic leukemia, its expression in other mature B-cell neoplasms appears to be rare. We report a 74-year-old female with B-cell prolymphocytic leukemia (B-PLL) expressing CD13 antigen. On admission, splenomegaly was noted. Hematological examination revealed a platelet count of 90 x 10(9)/l and a white cell count of 68 x 10(9)/l with 73% PLL cells. The hemoglobin concentration was 10.6 g/dl. A bone marrow aspirate showed a normocellular marrow with 64% PLL cells. Surface marker analysis of the PLL cells was positive for CD11b, CD13, CD19, CD20, CD24, HLA-DR, FMC7, mu and lambda. Simultaneous expression of CD13 and CD19 antigen was confirmed by dual color flow cytometry. Southern blot analysis of DNA from circulating mononuclear cells gave a rearranged band for the immunoglobulin gene (JH) but not for TCR-beta. Cytogenetic analysis of marrow cells showed an abnormal karyotype involving numbers 1, 7, 10, 12, 14, 15 chromosomes.

UI MeSH Term Description Entries
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000944 Antigens, Differentiation, B-Lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin. Antigens, Differentiation, B-Cell,B-Cell Differentiation Antigens,B-Lymphocyte Differentiation Antigens,Blast-2 Antigen, B-Cell,Differentiation Antigens, B-Cell,Differentiation Antigens, B-Lymphocyte,Leu Antigens, B-Lymphocyte,Plasma Cell Antigens PC-1,Antigens, Differentiation, B Lymphocyte,Antigens, Plasma Cell, PC-1,B-Cell Blast-2 Antigen,Antigen, B-Cell Blast-2,Antigens, B-Cell Differentiation,Antigens, B-Lymphocyte Differentiation,Antigens, B-Lymphocyte Leu,B Cell Blast 2 Antigen,B Cell Differentiation Antigens,B Lymphocyte Differentiation Antigens,B-Lymphocyte Leu Antigens,Blast 2 Antigen, B Cell,Differentiation Antigens, B Cell,Differentiation Antigens, B Lymphocyte,Leu Antigens, B Lymphocyte,Plasma Cell Antigens PC 1
D015448 Leukemia, B-Cell A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood. B-Cell Leukemia,B-Lymphocytic Leukemia,Leukemia, Lymphocytic, B-Cell,Lymphocytic Leukemia, B-Cell,Leukemia, Lymphocytic, B Cell,B Cell Leukemia,B Lymphocytic Leukemia,B-Cell Leukemias,B-Cell Lymphocytic Leukemia,B-Cell Lymphocytic Leukemias,B-Lymphocytic Leukemias,Leukemia, B Cell,Leukemia, B-Cell Lymphocytic,Leukemia, B-Lymphocytic,Leukemias, B-Cell,Leukemias, B-Cell Lymphocytic,Leukemias, B-Lymphocytic,Lymphocytic Leukemia, B Cell,Lymphocytic Leukemias, B-Cell
D015463 Leukemia, Prolymphocytic A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA. Prolymphocytic Leukemia,Leukemias, Prolymphocytic,Prolymphocytic Leukemias
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D018826 CD13 Antigens Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide. ANPEP Protein,Aminopeptidase M,Aminopeptidase N,Antigens, CD13,Membrane Alanyl Aminopeptidase,Alanine Aminopeptidase,Alanyl Aminopeptidase,Amino-oligopeptidase,Aminooligopeptidase,CD13 Antigen,Antigen, CD13,Protein, ANPEP

Related Publications

A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
January 1998, Ryoikibetsu shokogun shirizu,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
January 1987, Hematologic pathology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
April 2023, Journal of hematology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
January 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
January 2011, Acta haematologica,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
March 1987, British journal of haematology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
November 2019, Blood,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
July 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
March 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Matsushita, and K Nagai, and T Ishikawa, and E Tatsumi, and Y Ohno, and T Takahashi
March 1997, Blood,
Copied contents to your clipboard!